AbbVie: The Abbott Spinoff Arrives, But What’s Next?

It is now official – AbbVie exists. For those who may not recall, AbbVie is the so-called research-based pharma that has been spun off by Abbott Laboratories and features a portfolio of existing medicines, such as Humira and Synthroid, along with a pipeline of some 20 compounds in Phase II or Phase III development. One question, though, is what kind of shelf life will AbbVie actually have? On one hand, there is Humira, a biologic that is approved to treat rheumatoid arthritis, psoriasis and Crohn’s disease, where the average treatment penetration rate is below 20 percent, notes Damien Conover, who heads pharma research at Morningstar, in an investor report today. And Humira is a huge seller that is expected to generate some $10 billion in sales this year alone, reflecting the growth potential in those illnesses. And while patent protection expires in 2016, the medication is a complex biologic, suggesting the likelihood that generic rivals will appear immediately may not be high. Then again, Abbott (ABT) – or AbbVie – is not taking any chances. Last year, the drugmaker petitioned the FDA not to approve any biosimilar for Humira on the grounds that the FDA would have no choice but to use trade secrets submitted to the agency when approval for Humira was first sought (back story). And recently, Pfizer won approval for its Xeljanz pill for RA (see this). Meanwhile, AbbVie (ABBV) cardiovascular drugs – Tricor, Trilipix and Niaspan – represent 1...
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Abbott Laboratories Abbvie Humira Pfizer Rheumatoid Arthritis Source Type: blogs

Related Links:

Authors: Shi YQ, Qi WF, Kong CY Abstract Rheumatoid arthritis (RA), which normally manifests as a multi‑joint inflammatory reaction, is a common immunological disease in clinical practice. However, the pathogenesis of RA has not yet been fully elucidated. Rituximab (RTX) is an effective drug in the treatment of RA, however its therapeutic efficacy and mechanism of action require further investigation. Thus, the present study aimed to screen the candidate key regulatory genes and explain the potential mechanisms of RA. Gene chips of RA and normal joint tissues were analyzed and, gene chips of RTX before and after ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
CONCLUSIONS: Treatment failure risk was lower in patients with idiopathic noninfectious uveitis receiving adalimumab versus those receiving placebo. PMID: 32469621 [PubMed - as supplied by publisher]
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
Authors: Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH Abstract Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomiz...
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
Authors: Sekiguchi Y, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, Inano T, Fukuda Y, Shirane S, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Sekiguchi N, Noguchi M Abstract A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6. She was started on methotrexate (MTX) in X-1. She developed a cough, and chest computed tomography showed abnormalities. In X, MTX was discontinued, but the cough persisted. A lung biopsy revealed a diagnosis of nodular sclerosis classic Hodgkin lymphoma (CHL-NS). She was considered to have "other iatrogenic immunodeficiency-associated lymphoproli...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 25 May 2020Source: The Brazilian Journal of Infectious DiseasesAuthor(s): Ludy Vargas, Fernanda Bastos, André Guimarães, Sávio Amaral, Tarcisio Fausto, Maria Arriaga, Manoel Sarno, Carlos Brites
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
CONCLUSION: MiR-98-5p inhibits the secretion of HBV, proliferation, migration, and invasion of HBV-HCC cells by targeting NIK. PMID: 32469170 [PubMed - in process]
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Abstract Autophagy, one mechanism of programmed cell death, is fundamental to cellular homeostasis. Previous studies have identified autophagy as a novel mechanism by which cytokines control the immune response. However, its precise role in immune-related inflammatory skin diseases such as psoriasis remains unclear. Thus, this study explored the functional role of autophagy in psoriatic inflammation of epidermal keratinocytes. Strong light chain 3 immunoreactivity was observed in epidermal keratinocytes of both human psoriatic lesions and imiquimod-induced mice psoriatic model, and it was readily induced by polycy...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Authors: Stefano ML, Kream RM, Stefano GB Abstract The emergence of the novel ß-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nACh...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 28 May 2020Source: The Egyptian RheumatologistAuthor(s): Rasha M. Fawzy, Gamal A. Hammad, Samy E. Egila, Amira N. Elkasas, Nehad A. Fouad
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Crohn's Disease | Heart | Hepatitis | Hepatitis C | Humira | Mergers and Aquisitions | Niaspan | Partnerships | Pfizer | Pharma Commentators | Pharmaceuticals | Psoriasis | Rheumatoid Arthritis | Rheumatology | Synthroid | Tricor | Trilipix